Literature DB >> 33237039

Clinical and prognostic pan-cancer analysis of m6A RNA methylation regulators in four types of endocrine system tumors.

Kai Li1,2,3,4, Haiqing Luo4, Hui Luo2,3, Xiao Zhu1,2,3.   

Abstract

N6-methyladenosine (m6A), internal modification of mRNA, has recently been reported to be an important regulatory mechanism affecting tumor proliferation. However, its role in endocrine system tumors is poorly understood. We obtained datasets for four types tumors from the TCGA database, analyzed the GTEx database as a supplement to the control group, and used "Perl" and "R" software to analyze the datasets. Then we differentiated the expression level, used it to cluster consensus. Besides, we established lasso regression model to screen variables, used univariate and multivariate cox analyses to explore the independent risk factors associated with cancer prognosis. The results indicated that except for WTAP, the expression level of METTL3 was negatively correlated with other genes. The expression level of WTAP and METTL16 was positively correlated with overall survival (OS). Moreover, we found that different clinical subtypes of adrenal cortical carcinoma had significant differences in survival status, histologic grading, pathological T grade, and OS. Furthermore, different clinical subtypes of thyroid carcinoma had significant differences in histologic grading and pathological T grade. The differential expression of m6A regulatory genes is closely associated with the presence of endocrine-system-related tumors, and risk scores can be used to assess prognosis.

Entities:  

Keywords:  endocrine system tumors; m6A methylation regulators; pan-cancer analysis; prognosis; risk score

Mesh:

Substances:

Year:  2020        PMID: 33237039      PMCID: PMC7762517          DOI: 10.18632/aging.104064

Source DB:  PubMed          Journal:  Aging (Albany NY)        ISSN: 1945-4589            Impact factor:   5.682


  51 in total

1.  Selection of important variables and determination of functional form for continuous predictors in multivariable model building.

Authors:  Willi Sauerbrei; Patrick Royston; Harald Binder
Journal:  Stat Med       Date:  2007-12-30       Impact factor: 2.373

2.  Cancer statistics, 2020.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2020-01-08       Impact factor: 508.702

3.  Identification of entacapone as a chemical inhibitor of FTO mediating metabolic regulation through FOXO1.

Authors:  Shiming Peng; Wen Xiao; Dapeng Ju; Baofa Sun; Nannan Hou; Qianlan Liu; Yanli Wang; Haijiao Zhao; Chunchun Gao; Song Zhang; Ran Cao; Pengfei Li; Huanwei Huang; Yongfen Ma; Yankai Wang; Weiyi Lai; Zhixiong Ma; Wei Zhang; Song Huang; Hailin Wang; Zhiyuan Zhang; Liping Zhao; Tao Cai; Yong-Liang Zhao; Fengchao Wang; Yongzhan Nie; Gang Zhi; Yun-Gui Yang; Eric Erquan Zhang; Niu Huang
Journal:  Sci Transl Med       Date:  2019-04-17       Impact factor: 17.956

Review 4.  The emerging molecular mechanism of m6A modulators in tumorigenesis and cancer progression.

Authors:  Shuiping Liu; Qiujie Li; Ke Chen; Qin Zhang; Guohua Li; Lvjia Zhuo; Bingtao Zhai; Xinbing Sui; Xiaotong Hu; Tian Xie
Journal:  Biomed Pharmacother       Date:  2020-04-13       Impact factor: 6.529

Review 5.  m6A Modification in Coding and Non-coding RNAs: Roles and Therapeutic Implications in Cancer.

Authors:  Huilin Huang; Hengyou Weng; Jianjun Chen
Journal:  Cancer Cell       Date:  2020-03-16       Impact factor: 31.743

6.  ALKBH5 Holds Prognostic Values and Inhibits the Metastasis of Colon Cancer.

Authors:  Peipei Yang; Qian Wang; Aihua Liu; Jun Zhu; Jinzhou Feng
Journal:  Pathol Oncol Res       Date:  2019-09-10       Impact factor: 3.201

Review 7.  Treatment of Adrenocortical Carcinoma.

Authors:  Anand Vaidya; Matthew Nehs; Kerry Kilbridge
Journal:  Surg Pathol Clin       Date:  2019-09-27

8.  m6A mRNA methylation regulates AKT activity to promote the proliferation and tumorigenicity of endometrial cancer.

Authors:  Jun Liu; Mark A Eckert; Bryan T Harada; Song-Mei Liu; Zhike Lu; Kangkang Yu; Samantha M Tienda; Agnieszka Chryplewicz; Allen C Zhu; Ying Yang; Jing-Tao Huang; Shao-Min Chen; Zhi-Gao Xu; Xiao-Hua Leng; Xue-Chen Yu; Jie Cao; Zezhou Zhang; Jianzhao Liu; Ernst Lengyel; Chuan He
Journal:  Nat Cell Biol       Date:  2018-08-27       Impact factor: 28.824

Review 9.  Detection of N6‑methyladenosine modification residues (Review).

Authors:  Wei Zhu; Jing-Zi Wang; Zhiqiang Xu; Mengda Cao; Qiaoli Hu; Chen Pan; Miao Guo; Ji-Fu Wei; Haiwei Yang
Journal:  Int J Mol Med       Date:  2019-04-18       Impact factor: 4.101

10.  N6-methyladenosine modification of circNSUN2 facilitates cytoplasmic export and stabilizes HMGA2 to promote colorectal liver metastasis.

Authors:  Ri-Xin Chen; Xin Chen; Liang-Ping Xia; Jia-Xing Zhang; Zhi-Zhong Pan; Xiao-Dan Ma; Kai Han; Jie-Wei Chen; Jean-Gabrie Judde; Olivier Deas; Feng Wang; Ning-Fang Ma; Xinyuan Guan; Jing-Ping Yun; Feng-Wei Wang; Rui-Hua Xu
Journal:  Nat Commun       Date:  2019-10-16       Impact factor: 14.919

View more
  11 in total

1.  A signature based on m6A pattern and tumor microenvironment infiltration in clear cell renal cell carcinoma.

Authors:  Chen Yang; Tian Yu; Qingwen Li; Fang Xie; Qin Lin
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

2.  High expression of COMMD7 is an adverse prognostic factor in acute myeloid leukemia.

Authors:  Kongfei Li; Lieguang Chen; Hua Zhang; Lu Wang; Keya Sha; Xiaohong Du; Daiyang Li; Zhongzheng Zheng; Renzhi Pei; Ying Lu; Hongyan Tong
Journal:  Aging (Albany NY)       Date:  2021-04-23       Impact factor: 5.682

Review 3.  METTL16, Methyltransferase-Like Protein 16: Current Insights into Structure and Function.

Authors:  Agnieszka Ruszkowska
Journal:  Int J Mol Sci       Date:  2021-02-22       Impact factor: 5.923

4.  Clinical and Prognostic Pan-Cancer Analysis of N6-Methyladenosine Regulators in Two Types of Hematological Malignancies: A Retrospective Study Based on TCGA and GTEx Databases.

Authors:  Xiangsheng Zhang; Liye Zhong; Zhilin Zou; Guosheng Liang; Zhenye Tang; Kai Li; Shuzhen Tan; Yongmei Huang; Xiao Zhu
Journal:  Front Oncol       Date:  2021-03-18       Impact factor: 6.244

Review 5.  Non-Coding RNA m6A Modification in Cancer: Mechanisms and Therapeutic Targets.

Authors:  Da-Hong Chen; Ji-Gang Zhang; Chuan-Xing Wu; Qin Li
Journal:  Front Cell Dev Biol       Date:  2021-12-22

6.  m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer.

Authors:  Zhihui Zhang; Chaoqi Zhang; Yuejun Luo; Peng Wu; Guochao Zhang; Qingpeng Zeng; Lide Wang; Zhaoyang Yang; Liyan Xue; Bo Zheng; Hua Zeng; Fengwei Tan; Qi Xue; Shugeng Gao; Nan Sun; Jie He
Journal:  BMC Med       Date:  2021-11-22       Impact factor: 8.775

7.  m6A regulator-mediated methylation modification patterns and tumor immune microenvironment in sarcoma.

Authors:  Zhehong Li; Junqiang Wei; Honghong Zheng; Xintian Gan; Mingze Song; Yafang Zhang; Lingwei Kong; Chao Zhang; Jilong Yang; Yu Jin
Journal:  Aging (Albany NY)       Date:  2022-01-03       Impact factor: 5.682

8.  Identified Gefitinib Metabolism-Related lncRNAs can be Applied to Predict Prognosis, Tumor Microenvironment, and Drug Sensitivity in Non-Small Cell Lung Cancer.

Authors:  Weilong Ye; Zhengguo Wu; Pengbo Gao; Jianhao Kang; Yue Xu; Chuzhong Wei; Ming Zhang; Xiao Zhu
Journal:  Front Oncol       Date:  2022-07-01       Impact factor: 5.738

Review 9.  RNA methyltransferase METTL16: Targets and function.

Authors:  Emily R Satterwhite; Kyle D Mansfield
Journal:  Wiley Interdiscip Rev RNA       Date:  2021-07-06       Impact factor: 9.349

10.  The Regulators Associated With N6-Methyladenosine in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma Reveal New Clinical and Prognostic Markers.

Authors:  Shuzhen Tan; Zesong Li; Kai Li; Yingqi Li; Guosheng Liang; Zhenye Tang; Jianhao Kang; Wenqing Chen; Minhua Li; Zhilin Zou; Guoliang Pi; Xiao Zhu
Journal:  Front Cell Dev Biol       Date:  2021-12-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.